LienTeh.net > Ads > Generic (Eltrombopag) ELTROMDX 50

Generic (Eltrombopag) ELTROMDX 50

Inquire / Price

Model Number：

RL1020230315250
Brand Name：

ELTROMDX 50
Origin：

Generic drug, LAOS.
Small Orders：

Small order has available
Tags：

Thrombocytopenia

Inquire Now Link

Poster

Details
Description

Packaging Size

28T/bottle
Strength

50mg
Compositon

Eltrombopag
Treatment

Chronic Immune Thrombocytopenia (ITP),Severe Aplastic Anemia,Chronic Hepatitis C-associated Thrombocytopenia
Form

Tablet
Brand

ELTROMDX 50
Quantity Unit

50mg*28T/bottle
Manufacturer

BIGBEAR Pharma,Laos PDR

Contents hide

1 Chronic Immune Thrombocytopenia (ITP)

2 Chronic Hepatitis C-associated Thrombocytopenia

3 Severe Aplastic Anemia

3.1 First-line therapy

3.2 Refractory SAA

Eltrombopag is used to treat thrombocytopenia (a low blood platelet count) in adults and children with chronic immune thrombocytopenic purpura that did not get better with other treatment.

Chronic Immune Thrombocytopenia (ITP)

Indicated in patients with insufficient response to corticosteroids, immunoglobulins, or splenectomy

Use only in patients with ITP whose clinical condition increases bleeding risk

Initial: 50 mg PO qDay

Maintenance: Adjust dose to achieve and maintain platelet count (Plt) >50 x 10^9/L to reduce risk of bleeding; not to exceed 75 mg/day

Chronic Hepatitis C-associated Thrombocytopenia

Indicated to allow initiation and maintenance of interferon-based therapy

Initial: 25 mg PO qDay

Adjust dose in 25 mg increments q2weeks PRN to achieve target platelet count required to initiate/maintain antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day

During antiviral therapy, adjust dose to avoid dose reductions of peginterferon

Severe Aplastic Anemia

First-line therapy

First-line treatment, in combination with standard immunosuppressive therapy, for patients with severe aplastic anemia (SAA)
Initial dose: 150 mg PO qDay for 6 months
Do not exceed initial dose; total duration is 6 months

Refractory SAA

Indicated for SAA in patients who fail to respond adequately to at least 1 prior immunosuppressive therapy
Initial dose: 50 mg PO qDay
Adjust dose in 50-mg increments q2Weeks PRN to achieve target Plt ≥50 x 10^9/L as necessary; not exceed 150 mg/day; may take up to 16 weeks for hematologic response